Serina Therapeutics, Inc. (SER)

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.

Ticker
SER
Exchange
NYSE
Sector
Healthcare
Industry
Biotechnology
Market cap
$36.44M
52-week range
$1.14 - $4.26

Valuation

Share price
$1.35 (close of Nov 18, 2026)
P/E (TTM)
-0.79x
Price to book
2.62x
Price to free cash flow
-1.60x
Enterprise value
$20.41M
Book value per share
$0.53

Price performance

PeriodChange
1 day-1.46%
5 days-10.00%
1 month-21.51%
3 months-48.47%
6 months-10.60%
Year to date-29.32%
1 year-64.10%
3 years-91.22%
5 years-95.08%
All time-98.60%

Short interest

As of
Oct 30, 2026
Short % of float
0.21%
Shares short
46.79K
Days to cover
0.81
Change since prior report
+6.65%
Source
FINRA consolidated short interest

Profitability and growth

Return on assets
-275.96%
Net margin
-14,755.38%
EBITDA margin
-18,401.54%
Revenue growth
132.14%

Cash flow and balance sheet

Free cash flow yield (TTM)
-62.66%
Current ratio
4.62x
Net debt to EBITDA
0.68x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$130.00K
EBITDA
-$23.92M
Net income
-$19.18M
Research and development
$13.15M
Interest expense
$213.00K

Income statement by year

Period endRevenueGross profitNet income
2025-12-31$130.00K--$19.18M
2024-12-31$56.00K--$11.14M
2023-12-31--$5.27M
2022-12-31$34.00K$21.00K-$10.46M
2021-12-31$144.00K$125.00K-$8.68M
2020-12-31$361.00K$335.00K-$10.87M
2019-12-31$1.73M$1.48M-$12.15M
2018-12-31$1.40M$1.03M-$7.50M
2017-12-31$1.40M$1.24M-$6.58M
2016-12-31$1.67M--$15.49M

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-31--14,755.38%--
2024-12-31--19,894.64%--
2022-12-3161.76%-30,770.59%--
2021-12-3186.81%-6,024.31%--
2020-12-3192.80%-3,009.70%--
2019-12-3185.88%-703.36%--
2018-12-3173.93%-537.39%-91.14%-136.62%
2017-12-3188.03%-468.66%-79.10%-80.09%
2016-12-31--929.89%--

Cash and debt by year

Period endCashDebt
2025-12-31$3.06M$2.95M
2024-12-31$3.67M-
2023-12-31$7.62M$2.98M
2022-12-31$645.00K$18.12M
2021-12-31$584.00K$13.20M
2020-12-31$527.00K-
2019-12-31$2.35M-
2018-12-31$6.71M-
2017-12-31$7.38M-
2016-12-31$259.00K-

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31-$18.01M$3.79M
2024-12-31-$17.16M$2.60M
2023-12-31-$2.98M$25.00K
2022-12-31-$5.94M$760.00K
2021-12-31-$7.86M$999.00K
2020-12-31-$7.84M$909.00K
2019-12-31-$10.80M$1.91M
2018-12-31-$8.02M$1.28M
2017-12-31-$6.29M$114.00K
2016-12-31-$8.45M-

Investor relations

Next earnings report

Next confirmed report
Nov 19, 2026

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-12Sep 2026-
2026-08-13Jun 2026-
2026-05-14Mar 2026-
2026-03-25Dec 2025-
2025-11-13Sep 2025-$0.47
2025-08-11Jun 2025-$0.36
2025-05-08Mar 2025-
2025-03-24Dec 2024-

Filings and sources

Company website
serinatx.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades